HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Depressive disorder — Clinical Guidelines

Overview

Depressive disorder encompasses a range of mood disorders characterized by persistent sadness, loss of interest, and functional impairment. It significantly impacts quality of life and is associated with increased risk of suicide and other comorbidities.

Diagnosis

Key Symptoms: Persistent sadness, loss of interest, fatigue, changes in appetite or sleep, feelings of worthlessness, difficulty concentrating 1 3 5.

Recommended Tests: No specific laboratory tests; diagnosis primarily clinical using structured interviews like MINI 1 15.

Grading: Severity assessed using scales such as PHQ-9 for monitoring progression and treatment response 1 15.

Management

First-Line Treatments:

- Selective Serotonin Reuptake Inhibitors (SSRIs): Commonly used in adults and children/adolescents, with careful monitoring of dosing in pediatric populations 8 19. - Psychotherapy: Cognitive Behavioral Therapy (CBT) and interpersonal therapy are recommended adjuncts 9 20.

Adjunctive Treatments:

- B Vitamins: Considered for their potential role in addressing deficiencies linked to depressive disorder 3. - Nutraceuticals: Emerging evidence supports certain nutraceuticals as adjuncts, though comparative efficacy varies 2. - Bright Light Therapy (BLT): Shown to be effective as an adjunctive treatment for nonseasonal depressive disorders 1. - Transcutaneous Auricular Vagus Nerve Stimulation (taVNS): Demonstrates promise in efficacy and safety for depression 7. - Racemic Ketamine: Emerging as a potential rapid-acting therapy for treatment-resistant depression 4.

Special Populations

Pediatrics: SSRIs require careful dosing adjustments; fluoxetine concentration is notably higher in children compared to adults 8.

Elderly: Increased risk of polypharmacy and associated complications; careful monitoring of medication use is essential 11.

Comorbidities: Specific attention to psychosocial stressors, particularly work-related factors, which may influence depressive symptoms 12.

Key Recommendations

Use SSRIs as first-line pharmacological treatment for depressive disorders in adults and adolescents with close monitoring of side effects and dosing in pediatric patients (Evidence: Strong 8 19).

Consider adjunctive therapies such as B vitamins and specific nutraceuticals based on individual patient profiles and deficiency states (Evidence: Moderate 3 2).

Evaluate and implement bright light therapy for nonseasonal depressive disorders when standard treatments are insufficient (Evidence: Moderate 1).

Explore transcutaneous auricular vagus nerve stimulation (taVNS) as a safe and potentially effective adjunctive treatment option (Evidence: Moderate 7).

Screen for and address psychosocial stressors, especially in the workplace, as they may contribute significantly to depressive symptoms (Evidence: Moderate 12).

References

1 Menegaz de Almeida A, Aquino de Moraes FC, Cavalcanti Souza ME, Cavalcanti Orestes Cardoso JH, Tamashiro F, Miranda C et al.. Bright Light Therapy for Nonseasonal Depressive Disorders: A Systematic Review and Meta-Analysis. JAMA psychiatry 2025. link 2 Cheng YC, Huang WL, Chen WY, Huang YC, Kuo PH, Tu YK. Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysis. Psychological medicine 2025. link 3 Zheng ZQ, Shen L, Zhao LM, Ji HF. B vitamins as adjunct therapies for depressive disorder. Trends in endocrinology and metabolism: TEM 2025. link 4 Gałecki P, Bliźniewska-Kowalska KM, Cubała WJ, Depukat A, Mosiołek A, Rybakowski J et al.. Polish standard of treatment with racemic ketamine for patients with depressive disorders developed by a Working Group appointed by the National Consultant in the field of psychiatry. Psychiatria polska 2024. link 5 Riera-Serra P, Navarra-Ventura G, Castro A, Gili M, Salazar-Cedillo A, Ricci-Cabello I et al.. Clinical predictors of suicidal ideation, suicide attempts and suicide death in depressive disorder: a systematic review and meta-analysis. European archives of psychiatry and clinical neuroscience 2024. link 6 Gao M, Wang J, Liu P, Tu H, Zhang R, Zhang Y et al.. Gut microbiota composition in depressive disorder: a systematic review, meta-analysis, and meta-regression. Translational psychiatry 2023. link 7 Tan C, Qiao M, Ma Y, Luo Y, Fang J, Yang Y. The efficacy and safety of transcutaneous auricular vagus nerve stimulation in the treatment of depressive disorder: A systematic review and meta-analysis of randomized controlled trials. Journal of affective disorders 2023. link 8 Janas-Kozik MH, Słopień A, Remberk B, Siwek M. The place of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depressive disorders in children and adolescents. Recommendations of the Main Board of the Polish Psychiatric Association. Part 2 - pharmacological properties and safety of use. Psychiatria polska 2023. link 9 Wittenborn AK, Woods SB, Priest JB, Morgan PC, Tseng CF, Huerta P et al.. Couple and family interventions for depressive and bipolar disorders: Evidence base update (2010-2019). Journal of marital and family therapy 2022. link 10 Szulc A, Gałecki P, Samochowiec J, Dudek D. Letter to the Editor. Psychiatric emergency associated with depressive disorders. Psychiatria polska 2022. link 11 Ghaed-Sharaf M, Hariri S, Poustchi H, Nourollahi M, Khani S, Taherifard E et al.. The pattern of medication use, and determinants of the prevalence of polypharmacy among patients with a recent history of depressive disorder: results from the pars cohort study. BMC psychology 2022. link 12 Mikkelsen S, Coggon D, Andersen JH, Casey P, Flachs EM, Kolstad HA et al.. Are depressive disorders caused by psychosocial stressors at work? A systematic review with metaanalysis. European journal of epidemiology 2021. link 13 Chrétien P, Caillet P, Bouazzaoui F, Kaladjian A, Younes N, Sanchez S. [Is the orientation of patients suffering from depressive disorder to the psychiatric emergencies by a general practitioner associated with the decision to hospitalize?]. L'Encephale 2019. link 14 Vandevoorde J, Sanchez Valero A, Baudoin E, Kamar S, Chabert B, Baudoin T. Measurement of flow of thought in 68 patients monitored in post-emergency outpatient consultations: Role of ideational turmoil in the anxiety depressive symptomatology. L'Encephale 2018. link 15 Liu C, Liu M, Jiang R, Ma H, Wu X, Luan S et al.. Prevalence and Recognition of Depressive Disorder in Three Medical Outpatient Departments of General Hospitals in Beijing, China. The Journal of nervous and mental disease 2016. link 16 Bell S, Shipman M, Bystritsky A, Haifley T. Fluoxetine treatment and testosterone levels. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 2006. link 17 Yang CH, Tsai SJ, Chang JW, Hwang JP. Characteristics of Chinese suicide attempters admitted to a geropsychiatric unit. International journal of geriatric psychiatry 2001. link 18 Haghighat R. Lifelong development of risk of recurrence in depressive disorders. Journal of affective disorders 1996. link00082-1) 19 Harrington RC. Depressive disorder in children and adolescents. British journal of hospital medicine 1990. link 20 Böker W. Self-help attempts of depressive patients. Psychopathology 1986. link 21 Cantwell DP. Depressive disorders in children. Validation of clinical syndromes. The Psychiatric clinics of North America 1985. link 22 Crumley FE, Clevenger J, Steinfink D, Oldham D. Preliminary report on the dexamethasone suppression test for psychiatrically disturbed adolescents. The American journal of psychiatry 1982. link

Depressive disorder